C
옵티팜
153710KOSDAQ42.0 / 100
Reference Date: 2026-10-23
Financial Score15.5 / 40
News Sentiment12.5 / 25
Momentum4.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 10.4% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
OptiPharm operates in multiple sectors including animal disease diagnosis, pharmaceutical development, bacteriophages, Medipig, and VLP vaccines, offering technology-driven services and products. The company differentiates itself through proprietary diagnostic systems, gene-editing technologies for transgenic animal development, and an efficient vaccine production system.
Number of Employees
79people
Average Salary
59.9M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
2.48Industry Average 1.200.0Point
2.1x industry avg (risky)
ROE
-9.48Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
10.79Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20253.5 / 10 points
Revenue Growth Rate
2.5 / 3
Avg ▲13.4% (2-year basis)
Operating Profit Growth Rate
1.0 / 3
Avg ▲4.2% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -9.2% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (1%, downtrend)
Current 4,295Won52-week high 6,20052-week low 4,260
1-month return1.0Point
1m -10.43% (falling)
Volume trend2.0Point
Volume decreasing
Detailed Disclosure
0 totalPositive 0Neutral 0Negative 0